Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Buy
59
CCEL Quote, Financials, Valuation and Earnings
Last price:
$7.69
Seasonality move
:
-2.05%
Day range:
$7.69 - $7.88
52-week range:
$4.48 - $9.50
Dividend yield:
3.23%
P/E ratio:
--
P/S ratio:
2.01x
P/B ratio:
--
Volume:
1.4K
Avg. volume:
14.9K
1-year change:
31.8%
Market cap:
$62.5M
Revenue:
$31.3M
EPS (TTM):
-$1.12
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CCEL
Cryo-Cell International
|
$8M | $0.02 | 1.41% | -63.47% | $9.00 |
|
AMS
American Shared Hospital Services
|
$7.5M | $0.08 | 35.14% | -83.33% | -- |
|
ASTH
Astrana Health
|
$462.4M | $0.38 | 73.22% | -65.39% | $64.5000 |
|
BTMD
Biote
|
$51.4M | $0.20 | 12.23% | -5.56% | -- |
|
OMCL
Omnicell
|
$280.5M | $0.42 | 15.08% | 249.27% | -- |
|
PIII
P3 Health Partners
|
$358.1M | -- | 9.23% | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CCEL
Cryo-Cell International
|
$7.75 | $9.00 | $62.5M | -- | $0.25 | 3.23% | 2.01x |
|
AMS
American Shared Hospital Services
|
$3.21 | -- | $20.6M | 5.35x | $0.00 | 0% | 0.84x |
|
ASTH
Astrana Health
|
$33.4800 | $64.5000 | $1.5B | 25.75x | $0.00 | 0% | 0.93x |
|
BTMD
Biote
|
$5.96 | -- | $185.4M | 22.92x | $0.00 | 0% | 1.03x |
|
OMCL
Omnicell
|
$43.20 | -- | $2B | -- | $0.00 | 0% | 1.86x |
|
PIII
P3 Health Partners
|
$0.18 | -- | $29.8M | -- | $0.00 | 0% | 0.02x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CCEL
Cryo-Cell International
|
634.51% | -0.093 | 19.24% | 0.43x |
|
AMS
American Shared Hospital Services
|
45.9% | -0.001 | 90.05% | 1.35x |
|
ASTH
Astrana Health
|
38.34% | 1.507 | 17.07% | 1.84x |
|
BTMD
Biote
|
-1029.09% | 4.522 | 67.07% | 1.01x |
|
OMCL
Omnicell
|
31.72% | 0.182 | 28.33% | 0.87x |
|
PIII
P3 Health Partners
|
52.54% | 1.972 | 64.79% | 0.47x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CCEL
Cryo-Cell International
|
$6M | $1.7M | -212.19% | -- | 22.4% | -$911.8K |
|
AMS
American Shared Hospital Services
|
$1.4M | -$553K | 8.36% | 13.75% | -3.47% | -$407K |
|
ASTH
Astrana Health
|
$73.5M | $28.4M | 7.4% | 12.67% | 7.45% | $31.7M |
|
BTMD
Biote
|
$36.2M | $12.2M | 28.47% | -- | 37.75% | $13.6M |
|
OMCL
Omnicell
|
$122.3M | $6.6M | -1% | -1.47% | 2.32% | $9.4M |
|
PIII
P3 Health Partners
|
-- | -$107M | -20.12% | -26.35% | -27.84% | -$22.6M |
Cryo-Cell International vs. Competitors
-
Which has Higher Returns CCEL or AMS?
American Shared Hospital Services has a net margin of 8.15% compared to Cryo-Cell International's net margin of -2.96%. Cryo-Cell International's return on equity of -- beat American Shared Hospital Services's return on equity of 13.75%.
Company Gross Margin Earnings Per Share Invested Capital CCELCryo-Cell International74.83% $0.08 $2M AMSAmerican Shared Hospital Services19.57% -$0.03 $54.2M -
What do Analysts Say About CCEL or AMS?
Cryo-Cell International has a consensus price target of $9.00, signalling upside risk potential of 16.13%. On the other hand American Shared Hospital Services has an analysts' consensus of -- which suggests that it could grow by 40.19%. Given that American Shared Hospital Services has higher upside potential than Cryo-Cell International, analysts believe American Shared Hospital Services is more attractive than Cryo-Cell International.
Company Buy Ratings Hold Ratings Sell Ratings CCELCryo-Cell International0 0 0 AMSAmerican Shared Hospital Services0 0 0 -
Is CCEL or AMS More Risky?
Cryo-Cell International has a beta of 0.501, which suggesting that the stock is 49.887% less volatile than S&P 500. In comparison American Shared Hospital Services has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.72%.
-
Which is a Better Dividend Stock CCEL or AMS?
Cryo-Cell International has a quarterly dividend of $0.25 per share corresponding to a yield of 3.23%. American Shared Hospital Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International pays -- of its earnings as a dividend. American Shared Hospital Services pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCEL or AMS?
Cryo-Cell International quarterly revenues are $8M, which are larger than American Shared Hospital Services quarterly revenues of $7M. Cryo-Cell International's net income of $655.8K is higher than American Shared Hospital Services's net income of -$207K. Notably, Cryo-Cell International's price-to-earnings ratio is -- while American Shared Hospital Services's PE ratio is 5.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International is 2.01x versus 0.84x for American Shared Hospital Services. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCELCryo-Cell International2.01x -- $8M $655.8K AMSAmerican Shared Hospital Services0.84x 5.35x $7M -$207K
-
Which has Higher Returns CCEL or ASTH?
Astrana Health has a net margin of 8.15% compared to Cryo-Cell International's net margin of 3.36%. Cryo-Cell International's return on equity of -- beat Astrana Health's return on equity of 12.67%.
Company Gross Margin Earnings Per Share Invested Capital CCELCryo-Cell International74.83% $0.08 $2M ASTHAstrana Health15.35% $0.33 $945.2M -
What do Analysts Say About CCEL or ASTH?
Cryo-Cell International has a consensus price target of $9.00, signalling upside risk potential of 16.13%. On the other hand Astrana Health has an analysts' consensus of $64.5000 which suggests that it could grow by 92.65%. Given that Astrana Health has higher upside potential than Cryo-Cell International, analysts believe Astrana Health is more attractive than Cryo-Cell International.
Company Buy Ratings Hold Ratings Sell Ratings CCELCryo-Cell International0 0 0 ASTHAstrana Health10 2 0 -
Is CCEL or ASTH More Risky?
Cryo-Cell International has a beta of 0.501, which suggesting that the stock is 49.887% less volatile than S&P 500. In comparison Astrana Health has a beta of 1.134, suggesting its more volatile than the S&P 500 by 13.363%.
-
Which is a Better Dividend Stock CCEL or ASTH?
Cryo-Cell International has a quarterly dividend of $0.25 per share corresponding to a yield of 3.23%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International pays -- of its earnings as a dividend. Astrana Health pays out 102.24% of its earnings as a dividend.
-
Which has Better Financial Ratios CCEL or ASTH?
Cryo-Cell International quarterly revenues are $8M, which are smaller than Astrana Health quarterly revenues of $478.7M. Cryo-Cell International's net income of $655.8K is lower than Astrana Health's net income of $16.1M. Notably, Cryo-Cell International's price-to-earnings ratio is -- while Astrana Health's PE ratio is 25.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International is 2.01x versus 0.93x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCELCryo-Cell International2.01x -- $8M $655.8K ASTHAstrana Health0.93x 25.75x $478.7M $16.1M
-
Which has Higher Returns CCEL or BTMD?
Biote has a net margin of 8.15% compared to Cryo-Cell International's net margin of 20.83%. Cryo-Cell International's return on equity of -- beat Biote's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CCELCryo-Cell International74.83% $0.08 $2M BTMDBiote70.47% $0.33 -$8M -
What do Analysts Say About CCEL or BTMD?
Cryo-Cell International has a consensus price target of $9.00, signalling upside risk potential of 16.13%. On the other hand Biote has an analysts' consensus of -- which suggests that it could grow by 66.89%. Given that Biote has higher upside potential than Cryo-Cell International, analysts believe Biote is more attractive than Cryo-Cell International.
Company Buy Ratings Hold Ratings Sell Ratings CCELCryo-Cell International0 0 0 BTMDBiote0 0 0 -
Is CCEL or BTMD More Risky?
Cryo-Cell International has a beta of 0.501, which suggesting that the stock is 49.887% less volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CCEL or BTMD?
Cryo-Cell International has a quarterly dividend of $0.25 per share corresponding to a yield of 3.23%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International pays -- of its earnings as a dividend. Biote pays out 262.18% of its earnings as a dividend.
-
Which has Better Financial Ratios CCEL or BTMD?
Cryo-Cell International quarterly revenues are $8M, which are smaller than Biote quarterly revenues of $51.4M. Cryo-Cell International's net income of $655.8K is lower than Biote's net income of $10.7M. Notably, Cryo-Cell International's price-to-earnings ratio is -- while Biote's PE ratio is 22.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International is 2.01x versus 1.03x for Biote. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCELCryo-Cell International2.01x -- $8M $655.8K BTMDBiote1.03x 22.92x $51.4M $10.7M
-
Which has Higher Returns CCEL or OMCL?
Omnicell has a net margin of 8.15% compared to Cryo-Cell International's net margin of 3.06%. Cryo-Cell International's return on equity of -- beat Omnicell's return on equity of -1.47%.
Company Gross Margin Earnings Per Share Invested Capital CCELCryo-Cell International74.83% $0.08 $2M OMCLOmnicell43.29% $0.19 $1.8B -
What do Analysts Say About CCEL or OMCL?
Cryo-Cell International has a consensus price target of $9.00, signalling upside risk potential of 16.13%. On the other hand Omnicell has an analysts' consensus of -- which suggests that it could grow by 30.95%. Given that Omnicell has higher upside potential than Cryo-Cell International, analysts believe Omnicell is more attractive than Cryo-Cell International.
Company Buy Ratings Hold Ratings Sell Ratings CCELCryo-Cell International0 0 0 OMCLOmnicell0 0 0 -
Is CCEL or OMCL More Risky?
Cryo-Cell International has a beta of 0.501, which suggesting that the stock is 49.887% less volatile than S&P 500. In comparison Omnicell has a beta of 0.774, suggesting its less volatile than the S&P 500 by 22.577%.
-
Which is a Better Dividend Stock CCEL or OMCL?
Cryo-Cell International has a quarterly dividend of $0.25 per share corresponding to a yield of 3.23%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International pays -- of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCEL or OMCL?
Cryo-Cell International quarterly revenues are $8M, which are smaller than Omnicell quarterly revenues of $282.4M. Cryo-Cell International's net income of $655.8K is lower than Omnicell's net income of $8.6M. Notably, Cryo-Cell International's price-to-earnings ratio is -- while Omnicell's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International is 2.01x versus 1.86x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCELCryo-Cell International2.01x -- $8M $655.8K OMCLOmnicell1.86x -- $282.4M $8.6M
-
Which has Higher Returns CCEL or PIII?
P3 Health Partners has a net margin of 8.15% compared to Cryo-Cell International's net margin of -12.84%. Cryo-Cell International's return on equity of -- beat P3 Health Partners's return on equity of -26.35%.
Company Gross Margin Earnings Per Share Invested Capital CCELCryo-Cell International74.83% $0.08 $2M PIIIP3 Health Partners-- -$0.31 $397.3M -
What do Analysts Say About CCEL or PIII?
Cryo-Cell International has a consensus price target of $9.00, signalling upside risk potential of 16.13%. On the other hand P3 Health Partners has an analysts' consensus of -- which suggests that it could grow by 241.53%. Given that P3 Health Partners has higher upside potential than Cryo-Cell International, analysts believe P3 Health Partners is more attractive than Cryo-Cell International.
Company Buy Ratings Hold Ratings Sell Ratings CCELCryo-Cell International0 0 0 PIIIP3 Health Partners0 0 0 -
Is CCEL or PIII More Risky?
Cryo-Cell International has a beta of 0.501, which suggesting that the stock is 49.887% less volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CCEL or PIII?
Cryo-Cell International has a quarterly dividend of $0.25 per share corresponding to a yield of 3.23%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International pays -- of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCEL or PIII?
Cryo-Cell International quarterly revenues are $8M, which are smaller than P3 Health Partners quarterly revenues of $362.1M. Cryo-Cell International's net income of $655.8K is higher than P3 Health Partners's net income of -$46.5M. Notably, Cryo-Cell International's price-to-earnings ratio is -- while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International is 2.01x versus 0.02x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCELCryo-Cell International2.01x -- $8M $655.8K PIIIP3 Health Partners0.02x -- $362.1M -$46.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
